These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19636247)

  • 1. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
    Singh M; Arora R; Jawad E
    Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
    Ly T; Ruiz ME
    Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA; Su Z; Martin RL; Cox BF
    Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
    Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
    Kecskeméti V
    Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long QT syndrome and short QT syndrome.
    Zareba W; Cygankiewicz I
    Prog Cardiovasc Dis; 2008; 51(3):264-78. PubMed ID: 19026859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
    Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
    J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac K+ channels and drug-acquired long QT syndrome.
    Drici MD; Barhanin J
    Therapie; 2000; 55(1):185-93. PubMed ID: 10860023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.